Managing Director, MPM Capital
Founding partner, Brunnur Ventures
Managing Director, Bay City Capital
Managing Director, Head of Transactions & Legal, Novartis Venture Fund
Managing Partner at Hyfinity Investments
Managing Partner, Pivotal Bioventure Partners
General Partner at
Chief Executive Officer, Oculis
Dr. Sherif joined Oculis as Chief Executive Officer in 2017 from Novartis where he served as Entrepreneur in Residence at the Novartis Venture Fund. Since his arrival, the company raised over $100M USD, two successful Phase 2b trials were completed with OCS-01, a positive end-of-phase 2 meeting was conducted with the FDA propelling OCS-01 into Phase 3 for two distinct indications, the OPTIREACH® formulation technology was validated for both: the back- and the front-of-the-eye, and OCS-02, an antibody fragment anti-TNF alpha, was in-licensed from Novartis.
Prior to this, he held senior global positions in both Alcon, where he was President of Europe, Middle East and Africa, and Novartis, where he served as President of Novartis Pharmaceuticals, Canada. Dr. Sherif joined Novartis Pharmaceuticals in 2002 and has also held roles as Head of Transplant and Infectious Disease for Latin America, and President of the Novartis Vaccines and Diagnostics Division for Latin America. During his tenure in Canada and in Europe, he held several Chairman and Co-chair positions such as Vice Chairman for the Innovative Medicine Canada Association in Ottawa, Chairman of In-Vivo Montreal and Chairman of the Board Ophthalmic Surgery and Vision Care at Eucomed, Brussels.
Prior to Novartis, Dr. Sherif worked for several pharmaceutical companies, holding positions of increasing seniority, mainly in marketing and general management with international scope. Dr. Sherif is a medical doctor by training, and also has an MBA from IMD and a Specialized Master’s Degree in Medical Management.
Chief Executive Officer,
AMR Action Fund